Pharsight

Toviaz generic

Toviaz is an overactive bladder treatment drug owned by Pfizer. It contains the active ingredient fesoterodine fumarate and was authorized for market use on 31 October, 2008. Toviaz is available in the form of an extended release oral tablet and it has a total of eight patents, two of which have already expired.

When will Toviaz generic be available?

The generic version of Toviaz might become available after 07 December, 2027. This is based on the expiry date of the last patent of the drug, which is on 2027-12-07. The expired patents of Toviaz are US6858650*PED and US6858650.

Toviaz uses

Toviaz is primarily used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Its active ingredient, fesoterodine fumarate, helps in controlling these symptoms.

Toviaz patent expiration

Toviaz has a total of 8 drug patents, of which 2 have expired. The remaining patents are likely to protect the drug against generic competition until 07 December, 2027. Below are the details of the patent:

Litigations filed on Toviaz

Toviaz dosage

Want to ask something?